CClinicalTrials.gg
WithdrawnNCT06289647ARRETUpdated Mar 13, 2026

Azithromycin Reduction to Reach Elimination of Trachoma B

A Phase 4 interventional study of Azithromycin in Trachoma, sponsored by University of California, San Francisco. Withdrawn at 1 site in Democratic Republic of the Congo. Open to participants aged 1 Month to 9 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Study withdrawn (no participants enrolled) due to resources.
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
1 Month to 9 Years
Sex
All
01

Study summary

The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maniema, DRC. The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution.

02

Conditions studied

  • Trachoma

Browse trials for

03

Who can participate

Ages eligible
1 Month to 9 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Provision of appropriate informed consent
  • Stated willingness to comply with all study procedures
  • Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial

Exclusion criteria

Exclusion Criteria:

  • Does not consent to participation
  • Unwilling to comply with all study procedures
  • Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Azithromycin Continuation

    In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).

    Drug: Azithromycin

  • No intervention
    Azithromycin Discontinuation

    In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.

Interventions

  • DrugAzithromycin

    In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.

05

What researchers measure

Primary outcomes

  1. Ocular chlamydia measured in a population-based sample of 0-9 year-old children

    Assessed by PCR.

    Time frame: 36 months

Secondary outcomes

  1. Infectious load of chlamydia among 0-9-year-old children infected with ocular chlamydia

    Assessed by PCR.

    Time frame: 36 months

  2. Conjunctival inflammation

    Assessed from conjunctival photography. Clinical photographs of the conjunctiva will be assessed by masked graders according to the grading scale described by the WHO Simplified Grading System. The system includes five signs, each of which can be present or absent: Trachomatous inflammation - follicular Trachomatous inflammation-intense Trachomatous scarring Trachomatous trichiasis Corneal opacity

    Time frame: 36 months

06

Study locations

1 site
  • University of California, San Francisco
    Kindu, Maniema Province, Democratic Republic of the Congo
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06289647
Lead sponsor
University of California, San Francisco
Collaborators
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, National Eye Institute (NEI)
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Oct 2024 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Mar 13, 2026

Study contacts

Catherine Oldenburg, ScD, MPH
principal investigator · University of California, San Francisco
Thomas Lietman, MD
principal investigator · University of California, San Francisco
Elodie Lebas, RN
study director · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion